title: Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma.
abstract: Adult T-cell leukemia/lymphoma (ATLL) is a malignant proliferation of mature helper T lymphocytes,(1) and is caused by human T-lymphotropic virus type I (HTLV-I);(2) an HTLV-I infection endemic in the Caribbean, south-western Japan, South America and Africa.(3,4) Seroepidemiological studies suggest that it is also endemic in Brazil.(5) Although carriers of HTLV-I show polyclonal integration of virus in T lymphocytes, only patients with ATLL of various subtypes show monoclonal integration of HTLV-I in tumor cells.(6,7) Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphoproliferative diseases(8) with unknown etiology.(9) The two most common presentations of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS).(10-13) However, both CTCL categories can easily resemble ATLL. Therefore, in HTLV-I endemic areas, differentiation between ATLL and CTCL must be performed, as they have different prognoses and treatment approaches.(14).
authors.affiliation: Department of Dermatology, Discipline of Hematology and Hemotherapy, Universidade Federal de São Paulo -, Brazil.
authors.forename: F H
authors.initials: FH
authors.lastname: Sakamoto
authors.forename: G W B
authors.initials: GW
authors.lastname: Colleoni
authors.forename: S P
authors.initials: SP
authors.lastname: Teixeira
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: N S
authors.initials: NS
authors.lastname: Michalany
authors.forename: F A
authors.initials: FA
authors.lastname: Almeida
authors.forename: A K
authors.initials: AK
authors.lastname: Chiba
authors.forename: V
authors.initials: V
authors.lastname: Petri
authors.forename: M A
authors.initials: MA
authors.lastname: Fernandes
authors.forename: M S
authors.initials: MS
authors.lastname: Pombo-de-Oliveira
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001938:Brazil; D003520:Cyclophosphamide / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D004317:Doxorubicin / Q000627:therapeutic use; D019353:Endemic Diseases; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D009364:Neoplasm Recurrence, Local; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004279:DNA, Viral; D016898:Interferon-alpha; D015215:Zidovudine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone